SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing.
The round was led by Vensana Capital with participation from existing investor New Enterprise Associates. In conjunction with the funding, NEA Principal Dr. Tak Cheung, formerly a board observer, will now be joining the SpyGlass board along with Vensana Managing Partner Kirk Nielsen and Principal Cynthia Yee.
The company intends to use the funds to further advance development efforts of platform technology.
Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman, CEO, SpyGlass Ophthalmics is focused on the development of novel treatments for chronic ophthalmic diseases. The technology was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and spun off campus post Series A funding from New Enterprise Associates.
